BioSpace News Archive

Quest Diagnostics Incorporated, the world’s leading provider of diagnostic information services, announced that it will report fourth quarter and full year 2019 results on Thursday, January 30, 2020, before the market opens.

Centene Corporation announced the extension of the expiration date of the offers to exchange notes issued by WellCare Health Plans, Inc.

Funds Will Be Used to Accelerate Commercialization of the ZAP-X Robotic Surgical Platform for Non-Invasive Treatment of Brain Tumors Affecting More Than 2 Million Cancer Patients Worldwide

Mirum Pharmaceuticals, Inc. announced the pricing of its public offering of 2,400,000 shares of its common stock at a price to the public of $20.00 per share.

KDx Diagnostics, Inc., announced that the Food and Drug Administration has granted “Breakthrough Device” designation for its URO17™ Bladder Cancer Recurrence Test.

Osmotica Pharmaceuticals plc, a fully integrated biopharmaceutical company, announced the pricing of its public offering of 6,000,000 ordinary shares at a price to the public of $5.00 per share.

Apellis Pharmaceuticals, Inc. announced the pricing of its underwritten public offering of 9.5 million shares of its common stock at a public offering price of $37.00 per share, for total gross proceeds of $351.5 million, before deducting underwriting discounts and commissions and expenses payable by Apellis.